Overview

Open-label Adjunctive Zonisamide for Bipolar Disorder

Status:
Terminated
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Elan Pharmaceuticals
Treatments:
Zonisamide